Cancers MDPI Revenue and Competitors

Basel, Switzerland

Location

N/A

Total Funding

Publishing

Industry

Estimated Revenue & Valuation

  • Cancers MDPI's estimated annual revenue is currently $4.9M per year.(i)
  • Cancers MDPI's estimated revenue per employee is $170,100

Employee Data

  • Cancers MDPI has 29 Employees.(i)
  • Cancers MDPI grew their employee count by 7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.9M4615%N/AN/A
#2
$1.5M10-17%N/AN/A
#3
$1.5M100%N/AN/A
#4
$2.3M1633%N/AN/A
#5
$3.4M2011%N/AN/A
#6
$1.5M100%N/AN/A
#7
$20.7M85-11%N/AN/A
#8
$4.9M297%N/AN/A
#9
$1.1M913%N/AN/A
Add Company

What Is Cancers MDPI?

Cancers (ISSN 2072-6694; CODEN: CANCCT) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Cancers features (1) Original Articles reporting on novel and original findings; (2) Clinical Observations accompanied by analysis and discussion; (3) Communications reporting small scale studies that include important new information; (4) timely Reviews and Topical Issues on cutting edge fields in oncology. In addition, we accept well-designed studies showing meaningful but negative results. By doing this, we encourage scientists to share those data so that they would not need to repeat the experiments that somebody else has already done. The scope of Cancers includes (but is not limited to): Cancer pathophysiology Cancer causes Cancer diagnosis Cancer screening Cancer prognosis Cancer prevention, initiation, progression, and treatment

keywords:N/A

N/A

Total Funding

29

Number of Employees

$4.9M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cancers MDPI News

2022-03-22 - Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients

According to the findings in the MDPI Cancers 2021, ... confirming the relationship between the immune cells and biliary tract cancer cells.

2022-02-22 - Publisher cancels special issue honoring plagiarizing dean ...

MDPI was about to publish a special issue in one of its journals to fete the career of a retired dean. But after Retraction Watch informed...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A2938%N/A
#2
$3.7M294%N/A
#3
$4.5M3163%N/A
#4
$4.8M310%N/A
#5
N/A327%N/A